Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. - Wikidata - wikimedia - TriplyDB

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

http://www.wikidata.org/entity/Q46463050

about

Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation Double Roles of Macrophages in Human Neuroimmune Diseases and Their Animal Models CD8(+) T-Cells as Immune Regulators of Multiple Sclerosis Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System Remyelination therapy for multiple sclerosis Immune modulation of stem cells and regeneration Function of microglia and macrophages in secondary damage after spinal cord injury M1 and M2 immune activation in Parkinson's Disease: Foe and ally?Therapeutic effects of glatiramer acetate and grafted CD115⁺ monocytes in a mouse model of Alzheimer's disease.Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA)Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation Therapeutic decisions in multiple sclerosis: moving beyond efficacy Type II Activation of Macrophages and Microglia by Immune Complexes Enhances Th17 Biasing in an IL-6-Independent Manner Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE Identification of Orch3, a locus controlling dominant resistance to autoimmune orchitis, as kinesin family member 1C Rett syndrome and other autism spectrum disorders--brain diseases of immune malfunction?Trichuris suis induces human non-classical patrolling monocytes via the mannose receptor and PKC: implications for multiple sclerosis.Continuous retinoic acid induces the differentiation of mature regulatory monocytes but fails to induce regulatory dendritic cells Inhibitory role for GABA in autoimmune inflammation.T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis Pathologic heterogeneity persists in early active multiple sclerosis lesions Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis.The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth.Wound administration of M2-polarized macrophages does not improve murine cutaneous healing responses.Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.Immune regulation of multiple sclerosis by CD8+ T cells Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation.Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity.Neuroantigen-specific autoregulatory CD8+ T cells inhibit autoimmune demyelination through modulation of dendritic cell function.Inhibition of experimental autoimmune uveitis by amino acid copolymers Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology.Immunomodulation of antigen presenting cells promotes natural regulatory T cells that prevent autoimmune diabetes in NOD mice.

P2860

Q21135577-209062F0-D0FF-4863-8013-2181BE21EBD8 Q24644706-8DC1FF6C-3A68-4140-AD09-5065B5B068CF Q26749131-8599193D-5F67-4B40-AE17-28F1BD83968A Q26772339-6A067354-D785-45C3-B2FF-0D8E376693F7 Q26796667-5A50E96A-FAE2-41F6-92B5-0E5613A10EF0 Q26824246-8F424C81-2946-4EEB-95EB-E9AD01C2F4C4 Q27010686-611CC67B-E3E2-4D9D-9514-6A0A5195E8CD Q27024453-EF62EB68-C076-4EB1-9B82-E45C4BD3E352 Q27024667-945860E5-8326-4088-8D05-FBCDF3DD5ECB Q27303708-E4EBF429-1090-4DDC-BDDC-F14B1DE86CA2 Q27307172-C5EEC81A-7FCB-41D5-802A-5F5995413884 Q28308287-91411DFC-7C32-454C-86E7-A55604F8BDA8 Q28386583-815C0F4C-2DDC-45B8-B257-9AD1E1C07377 Q28481922-85C903D4-FCD1-4227-B122-DC5444F59154 Q28486389-9B5A68AF-F3DE-46D1-8EAD-D01E6F6721A5 Q28538415-DC3698E3-CABF-404C-AE89-6576635CC4B9 Q28541039-9EB9DFA5-1794-4FD5-975B-23ECD39D1EF7 Q28554661-6C08BEFB-39A1-42B5-85E4-5D8F2AB617AC Q28647160-5AF60BBE-B746-4F6A-8647-72F340273290 Q28741374-F5B25203-9A01-4498-87F7-F5C505023481 Q30422962-ECE46842-4B32-41ED-9567-85925B612330 Q30426525-F03389E7-0205-40A0-A5DA-6A60D1B415E0 Q30658854-25CE658A-3289-42B8-865D-887BE360F93B Q33592420-DC339C49-607C-4C03-B4F8-77ADB2243D9E Q33664659-4046EDEB-A867-45D6-8E61-B9330033DCB8 Q33723154-FF9FA8C8-9C1E-40C1-8F7A-F4A15F659652 Q33751539-5BA6C119-1289-4553-AF3F-043286774453 Q33804184-BE757FC1-EE3F-49AF-8F2D-093C88467D6F Q33835877-FFFBA797-5803-4094-810F-17F4F7409909 Q33896697-A51D92FF-545B-4364-9A61-ACA9D81B0B6B Q33961310-253EE590-E0AF-4DC5-9A98-837F57DE140D Q33988247-A4F23FC5-423A-434B-ADD3-CD93EF32DD55 Q34017004-8423BFEC-6D8B-4014-AAC8-7D8A9163969A Q34035137-ED17AAE7-51A2-477D-AEFA-0FD0780AA50E Q34055604-CB3A66BD-0A21-444B-BB43-3AE7C4AA8F2A Q34061505-8CC54B4F-C782-4C28-A23B-F836331FC822 Q34075707-7C105533-D36F-42FB-9628-CEE7842492F7 Q34083323-619BD437-D293-4AF9-A40F-5FEFDEBDB76E Q34096571-88E3BC91-9A5C-4053-8E42-AB804F81FB0B Q34166274-C6AD6A74-36EC-4026-AF83-09CD1B6F377A

P2860

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

http://www.wikidata.org/entity/Q46463050

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

@en

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

@nl

type

label

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

@en

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

@nl

prefLabel

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

@en

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

@nl

P1433

Q46463050-F2B533DA-E8FC-4F69-8561-5DC954525B21

P1476

Q46463050-993D9FAC-4F0B-4971-901B-747634419F60

P2093

Q46463050-169529F3-F849-464F-85A4-D643F894E09F

Q46463050-3AF165F9-A696-4737-8572-79B853B89B50

Q46463050-4F47977B-A0D3-4285-9B77-3A8F9943B0C6

Q46463050-788F8272-5614-42F4-AACA-873912007ED7

Q46463050-B115D607-919A-49BD-A8FB-97020D161684

Q46463050-CAB77532-BE49-43CF-968C-625040EE032C

Q46463050-CE51ECD7-9FE2-4DFF-9AB3-F38633A7A43C

Q46463050-D0B6028E-BAEE-4E48-9628-8B7B3BB8854D

Q46463050-F6F932F6-3A6C-4B1E-A4B7-B8EEFF564DA0

Q46463050-FEFC1029-1E08-4816-920B-A963634C40D0

P2860

Q46463050-10F576FD-8039-4905-965F-079A5624FFC8

Q46463050-2E1D3472-432A-4D20-9A4F-80E3A06405DE

Q46463050-779D42C4-9CBD-4C14-AE7D-2DD86731CDEA

Q46463050-A0D5AA85-A210-4591-B2DD-1E8FE512F3C5

Q46463050-C37E766C-E7B5-4532-B1CA-97C6EE364811

Q46463050-CC9B66F5-F478-4D62-8056-4EF9D0DEA5A7

Q46463050-D86AD85D-0185-40A6-ADA8-091385F1BEBE

P2888

Q46463050-8040ED3E-E5CC-4D33-9857-A7DF98D5ED13

P304

Q46463050-FFE51407-AEE1-48C0-A330-E3EC4D26ED96

P31

Q46463050-F87DE14C-269F-4C00-8C87-BA760931B3B5

P356

Q46463050-79016CCD-3580-4D7E-BFC8-896E6825D25E

P407

Q46463050-0A8C2193-B56D-4757-A002-749EAAAC5F72

P433

Q46463050-1374B4A2-6ABA-4905-98F4-85D665F3C2E7

P478

Q46463050-21B9BA19-E817-4673-A212-15BE312E63BE

P50

Q46463050-E0B522E0-B592-4AA2-8B1B-D51F6CB0774F

P577

Q46463050-74120D3C-1BA0-4A4E-B003-032CFEBD15A9

P5875

Q46463050-0E2BAD9B-5876-4B18-80B2-F14CA4E739F6

P698

Q46463050-5437037D-BF6D-4948-930E-4C23C0960FAB

P356

P1433

Nature Medicine

P1476

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

@en

P2093

Cynthia D Rundle

http://www.w3.org/2001/XMLSchema#string

Juan C Patarroyo

http://www.w3.org/2001/XMLSchema#string

Lawrence Steinman

http://www.w3.org/2001/XMLSchema#string

Linda Lee

http://www.w3.org/2001/XMLSchema#string

Martin S Weber

http://www.w3.org/2001/XMLSchema#string

Raymond A Sobel

http://www.w3.org/2001/XMLSchema#string

Sawsan Youssef

http://www.w3.org/2001/XMLSchema#string

Scott S Zamvil

http://www.w3.org/2001/XMLSchema#string

Shannon E Dunn

http://www.w3.org/2001/XMLSchema#string

Thomas Prod'homme

http://www.w3.org/2001/XMLSchema#string

P2860

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

STAT-1 alpha and IFN-gamma as modulators of TNF-alpha signaling in macrophages: regulation and functional implications of the TNF receptor 1:STAT-1 alpha complex.

Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.

Mechanisms of action of glatiramer acetate in multiple sclerosis.

Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells.

Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

Conditional ablation of MHC-II suggests an indirect role for MHC-II in regulatory CD4 T cell maintenance.

P2888

P304

935-943

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1620

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6163455

http://www.w3.org/2001/XMLSchema#string

P698

17676050

http://www.w3.org/2001/XMLSchema#string